Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients

Robert Zeiser, MD, Andreas Burchert, MD, Claudia Lengerke, MD, Mareike Verbeek, Kristina Maas-Bauer, MD, Stephan Metzelder, MD, Silvia Spoerl, MD, Markus Ditschkowski, MD, Matyas Ecsedi, MD, Katja Sockel, MD, Francis Ayuk, MD, Salem Ajib, MD, Flore Sicre de Fontbrune, MD, Il-Kang Na, MD, Livius Penter, MD, Udo Holtick, MD PhD, Dominik Wolf, MD, Esther Schuler, MD, Everett Meyer, MD PhD, Petya Apostolova, MD, Hartmut Bertz, MD, Reinhard Marks, Michael Luebbert, MD, Ralph M. Waesch, MD PhD, Christof Scheid, MD PhD, Friedrich Stölzel, MD, Rainer Ordemann, MD, Gesine Bug, MD, Guido Kobbe, MD, Robert Negrin, MD, Mats L Brune, Alexandros Spyridonidis, Annette Schmitt-Graeff, MD, Walter van der Velden, MD, Gerwin Huls, MD PhD, Stephan Mielke, MD, Goetz Ulrich Grigoleit, MD, Jurgen Kuball, MDPhD, Ryan P Flynn, PhD, Gabriele Ihorst, PhD, Jing Du, Bruce R. Blazar, MD, Renate Arnold, MD, Nicolaus Kröger, MD, Joerg Halter, MD, Gerard Socie, Dietrich Beelen, MD, Christian Peschel, MD, Andreas Neubauer, MD, Juergen Finke, MD, Justus Duyster, MD PhD, Nikolas von Bubnoff, MD

Blood (2015) 126 (23): 858.

https://doi.org/10.1182/blood.V126.23.858.858

Published: 2015

Journal Articles

Efficacy, Safety and Long Term Results of Prophylactic and Preemptive Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Acute Leukemia: A Registry-Based Evaluation on 343 Patients By the Acute Leukemia Working Party of EBMT

Blood (2015) 126 (23): 863.

https://doi.org/10.1182/blood.V126.23.863.863

Published: 2015

Journal Articles

Recipient Dendritic Cells Are Regulated By MiR-146a during Acute GvHD

Natalie Stickel, MSc, Kathrin Hanke, MSc, Martin Köhler, MSc, Gabriele Prinz, Dietmar Pfeifer, Annette Schmitt-Graeff, MD, Tilman Brummer, PhD, Juergen Finke, MD, Justus Duyster, MD PhD, Ulrich Salzer, MD, Robert Zeiser, MD

Blood (2015) 126 (23): 146.

https://doi.org/10.1182/blood.V126.23.146.146

Published: 2015

Journal Articles

Activity and Tolerability of Azacitidine in Patients Who Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplasia (MDS): a Survey from the European Society for Blood and Marrow Transplantation (EBMT

Charles Craddock, MDPhD, Myriam Labopin, MD, Mohamed Houhou, Marie Robin, MD PhD, Juergen Finke, Patrice Chevallier, MD PhD, Ibrahim Yakoub-Agha, MD PhD, Jean-Henri Bourhis, MD PhD, Henrik Sengelov, MDDSc, Didier Blaise, MD, Peter Dreger, MD, Michael Hallek, MD, Arnon Nagler, MD, N Kroger, Mohamad Mohty

Blood (2014) 124 (21): 2506.

https://doi.org/10.1182/blood.V124.21.2506.2506

Published: 2014

Journal Articles

Radioimmunotherapy In Relapsed/Refractory Mantle Cell Lymphoma Patients: Final Results Of a European MCL Network Phase II Trial

Simone Ferrero, Alessandro Pastore, Roswitha Forstpointner, M.D., Christian W. Scholz, Antonio Pezzutto, Lothar Bergmann, Lorenz Truemper, Juergen Finke, Ulrich Keller, Marco Ladetto, Wolfgang Hiddemann, M.D., Oliver Weigert, Michael Unterhalt, Martin Dreyling

Blood (2013) 122 (21): 4384.

https://doi.org/10.1182/blood.V122.21.4384.4384

Published: 2013

Journal Articles

Prognostic Value Of Five-Group Cytogenetic Risk Classification In Patients With MDS After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study Of The Chronic Malignancies Working Party Of The EBMT

Christian Koenecke, MD, Gudrun Göhring, MD, Liesbeth de Wreede, Anja van Biezen, Christof Scheid, MD, Liisa Volin, MD, Johan Maertens, MD, PhD, Juergen Finke, MD, Nicolaas PM Schaap, MD, PhD, Marie Robin, MD, PhD, Jakob R. Passweg, MD, Jan J Cornelissen, MD, PhD, Dietrich Beelen, MD, Michael Heuser, MD, Theo de Witte, MD, Nicolaus Kröger, MD

Blood (2013) 122 (21): 2092.

https://doi.org/10.1182/blood.V122.21.2092.2092

Published: 2013

Journal Articles

Second Allogeneic Stem Cell Transplantation (AlloSCT) In Patients With Relapsed Lymphoma After First Allosct. A Retrospective Study Of The EBMT Lymphoma Working Party

Kristin Horstmann, Ariane Boumendil, PhD, Herve Finel, Jane F. Apperley, MBChB, FRCP, FRCPath, Fabio Ciceri, MD, Juergen Finke, MD, Achiel Van Hoof, Norbert Ifrah, MD, Slawomira Kyrcz-Krzemien, MD, Gustavo Milone, Ghulam J Mufti, FRCP, FRCPath, Elizabeth Naparstek, MD, Reuven Or, MD, Nigel H Russell, MD, Peter Dreger, MD

Blood (2013) 122 (21): 4632.

https://doi.org/10.1182/blood.V122.21.4632.4632

Published: 2013

Journal Articles

Randomized Trial On GvHD Prophylaxis with or without Anti T Cell Globulin ATG Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Updated Results and Evaluation of the European Group for Blood and Marrow Transplantation (EBMT) Risk Score.

Juergen Finke, Claudia Schmoor, PhD, Wolfgang A. Bethge, MD, Hellmut Ottinger, MD, Matthias Stelljes, MD, Axel R. Zander, MD, Liisa Volin, Dominik Heim, MD, Rainer Schwerdtfeger, Hartmut Bertz, Olga Grishina, MD, Gerard Socie

Blood (2012) 120 (21): 3090.

https://doi.org/10.1182/blood.V120.21.3090.3090

Published: 2012

Journal Articles

Combined Effect of Mtor Inhibitors and FTI for the Growth Inhibition of T Cell Lymphoma - Involvement of Different Molecular Mechanisms According to the Lymphoma Subtype

Leonidas Zierock, Wolfgang Melchinger, Bettina Wehrle, Juergen Finke, Reinhard Marks

Blood (2012) 120 (21): 4870.

https://doi.org/10.1182/blood.V120.21.4870.4870

Published: 2012

Journal Articles

Immunohistochemical Expression of TCRβ Predicts Achievment of Complete Remission in Enteropathy-Associated T-Cell Lymphoma

Piotr Czapiewski, Paul Fisch, Reinhard Marks, Juergen Finke, Annette Schmitt-Graff

Blood (2012) 120 (21): 5101.

https://doi.org/10.1182/blood.V120.21.5101.5101

Published: 2012

Journal Articles

Genital Mucosa in Men Is a Frequent Target of Chronic Graft Versus Host Disease

Christiane Marks, Christian Leiber, Hartmut Bertz, Juergen Finke, Reinhard Marks

Blood (2012) 120 (21): 4183.

https://doi.org/10.1182/blood.V120.21.4183.4183

Published: 2012

Journal Articles

Clofarabine Containing Conditioning Regimen for Allo-SCT in AML/ALL Patients: A Survey From the Acute Leukemia Working Party of EBMT

Patrice Chevallier, Myriam Labopin, MD, MS, Stefanie Buchholz, Arnold Ganser, MD, Fabio Ciceri, MD, Bruno Lioure, Christoph Faul, MD, Gaelle Guillerm, Juergen Finke, MD, Anne Huynh, MD, Joerg Schubert, MD, Hans Jochem Kolb, MD, Emmanuelle Polge, Arnon Nagler, M.D., Mohamad Mohty, MD, PhD

Blood (2011) 118 (21): 3004.

https://doi.org/10.1182/blood.V118.21.3004.3004

Published: 2011

Journal Articles

Comparison of 5-Azacytidine Versus Allogeneic Hematopoietic Cell Transplantation In Elderly (≥ 60 years) Patients with De Novo High-Risk MDS - a Retrospective Matched Pair Analysis

Uwe Platzbecker, Johannes Schetelig, Juergen Finke, Rudolf Trenschel, Bart Lee Scott, Guido Kobbe, Kerstin Schaefer-Eckhart, Martin Bornhäuser, Raphael Itzykson, Ulrich Germing, Dietrich Beelen, Gerhard Ehninger, Pierre Fenaux, MD, PhD, H. Joachim Deeg, Lionel Ades

Blood (2010) 116 (21): 3500.

https://doi.org/10.1182/blood.V116.21.3500.3500

Published: 2010

Journal Articles

SNP Array Analysis In Unrelated HLA-Matched Transplanted Patients Reveals Loss of Patient- Specific Allele at the Mismatched Locus

Miguel Waterhouse, Dietmar Pfeifer, Milena Pantic, Florian Emmerich, Monika Engelhardt, Hartmut Bertz, PhD, Juergen Finke

Blood (2010) 116 (21): 4692.

https://doi.org/10.1182/blood.V116.21.4692.4692

Published: 2010

Journal Articles

Everolimus and Mycophenolate as GvHD Prophylaxis Results In Improved Control of Advanced Disease and Reduced Bacterial and Fungal Infectious Complications After Allogeneic Stem Cell Transplantation

Reinhard E Marks, Hartmut Bertz, Ralph M. Waesch, MD, Wolfgang Melchinger, Juergen Finke

Blood (2010) 116 (21): 1264.

https://doi.org/10.1182/blood.V116.21.1264.1264

Published: 2010

Journal Articles

“ATG16 L1 a Additional Risk Factor for TRM After allogeneic Stem Cell Transplantation”.

Karin Landfried, Martin Hausmann, Gerhard Rogler, Daniel Wolff, Anne M Dickinson, PhD, Matthew Collin, MD, PhD, Juergen Finke, Ernst Holler, PhD, Reinhard Andreesen, MD, PhD

Blood (2009) 114 (22): 1155.

https://doi.org/10.1182/blood.V114.22.1155.1155

Published: 2009

Journal Articles

High Impact of Human Leukocyte Antigen Matching On Overall Survival and Transplant Related Mortality in Allogeneic Hematopoietic Stem Cell Transplantation for CLL: Long-Term Study From the EBMT Registry.

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M, Stéphane Morisset, MSc, Dietger Niederwieser, MD, Vladimir Koza, MD, Tapani Ruutu, MD, Nigel H. Russell, MD, Leo Verdonck, MD, Donald Milligan, MD, Nathalie Dhedin, MD, Tomas Kozak, Marc Boogaerts, MD, PhD, Juergen Finke, MD, Valérie Dubois, MD, Anja van Biezen, Ronald Brand, Theo de Witte, MD, Peter Dreger, MD

Blood (2009) 114 (22): 2286.

https://doi.org/10.1182/blood.V114.22.2286.2286

Published: 2009

Journal Articles

Relevance of the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) On Non-Relapse Related Mortality (NRM) in Patients with Acute Lymphoblastic Leukemia (ALL) Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Complete Remission: Results From the GMALL Study Group.

Matthias Stelljes, MD, Mareike David, Renate Arnold, MD, Dietrich W Beelen, MD, Wolfgang A Bethge, MD, Martin Bornhäuser, MD, Jolanta Dengler, MD, Juergen Finke, MD, Hans J Kolb, MD, Karin Kolbe, MD, Nicolaus Kröger, MD, Dietger Niederwieser, MD, Wolf Rösler, MD, Rainer Schwerdtfeger, MD, Joachim Kienast, MD, Nicola Goekbuget, MD, Dieter Hoelzer, MD, PhD

Blood (2009) 114 (22): 3352.

https://doi.org/10.1182/blood.V114.22.3352.3352

Published: 2009

Journal Articles

Shift to a New Donor Does Not Improve the Outcome After Second Allogeneic Stem Cell Transplantation (alloSCT) in Acute Leukemia Relapse After a First Allosct – a Risk Factor Analysis by the German Stem Cell Registry (DRST).

Blood (2009) 114 (22): 3328.

https://doi.org/10.1182/blood.V114.22.3328.3328

Published: 2009

Journal Articles

Standard and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantations (HSCT) from Related and Unrelated Donors for Chronic Lymphocytic Leukemia (CLL). a Long-Term Follow-up (10 years) Study from the EBMT Registry. (CLL Sub-Committee on Behalf of EBMT CLWP)

Mauricette Michallet, MD, PhD, Quoc Hung Le, MD, Peter Dreger, Mohamad Sobh, PhD, Dietger Niederwieser, MD, Vladimir Koza, MD, Tapani Ruutu, Nigel H. Russell, MD, Leo Verdonck, Donald Milligan, MD, MBChB, Nathalie Dhedin, Tomas Kozak, MD, PhD, Marc Boogaerts, MD, PhD, Juergen Finke, Nathalie Tedone, Anja Van Biezen, Ronald Brand, Theo de Witte on behalfhe European Group for Blood Marrow Transplantation

Blood (2008) 112 (11): 566.

https://doi.org/10.1182/blood.V112.11.566.566

Published: 2008

NARROW

Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients

Efficacy, Safety and Long Term Results of Prophylactic and Preemptive Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Acute Leukemia: A Registry-Based Evaluation on 343 Patients By the Acute Leukemia Working Party of EBMT

Recipient Dendritic Cells Are Regulated By MiR-146a during Acute GvHD

Activity and Tolerability of Azacitidine in Patients Who Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplasia (MDS): a Survey from the European Society for Blood and Marrow Transplantation (EBMT

Radioimmunotherapy In Relapsed/Refractory Mantle Cell Lymphoma Patients: Final Results Of a European MCL Network Phase II Trial

Prognostic Value Of Five-Group Cytogenetic Risk Classification In Patients With MDS After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study Of The Chronic Malignancies Working Party Of The EBMT

Second Allogeneic Stem Cell Transplantation (AlloSCT) In Patients With Relapsed Lymphoma After First Allosct. A Retrospective Study Of The EBMT Lymphoma Working Party

Randomized Trial On GvHD Prophylaxis with or without Anti T Cell Globulin ATG Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Updated Results and Evaluation of the European Group for Blood and Marrow Transplantation (EBMT) Risk Score.

Combined Effect of Mtor Inhibitors and FTI for the Growth Inhibition of T Cell Lymphoma - Involvement of Different Molecular Mechanisms According to the Lymphoma Subtype

Immunohistochemical Expression of TCRβ Predicts Achievment of Complete Remission in Enteropathy-Associated T-Cell Lymphoma

Genital Mucosa in Men Is a Frequent Target of Chronic Graft Versus Host Disease

Clofarabine Containing Conditioning Regimen for Allo-SCT in AML/ALL Patients: A Survey From the Acute Leukemia Working Party of EBMT

Comparison of 5-Azacytidine Versus Allogeneic Hematopoietic Cell Transplantation In Elderly (≥ 60 years) Patients with De Novo High-Risk MDS - a Retrospective Matched Pair Analysis

SNP Array Analysis In Unrelated HLA-Matched Transplanted Patients Reveals Loss of Patient- Specific Allele at the Mismatched Locus

Everolimus and Mycophenolate as GvHD Prophylaxis Results In Improved Control of Advanced Disease and Reduced Bacterial and Fungal Infectious Complications After Allogeneic Stem Cell Transplantation

“ATG16 L1 a Additional Risk Factor for TRM After allogeneic Stem Cell Transplantation”.

High Impact of Human Leukocyte Antigen Matching On Overall Survival and Transplant Related Mortality in Allogeneic Hematopoietic Stem Cell Transplantation for CLL: Long-Term Study From the EBMT Registry.

Shift to a New Donor Does Not Improve the Outcome After Second Allogeneic Stem Cell Transplantation (alloSCT) in Acute Leukemia Relapse After a First Allosct – a Risk Factor Analysis by the German Stem Cell Registry (DRST).

Standard and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantations (HSCT) from Related and Unrelated Donors for Chronic Lymphocytic Leukemia (CLL). a Long-Term Follow-up (10 years) Study from the EBMT Registry. (CLL Sub-Committee on Behalf of EBMT CLWP)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only